

OBSERVATIONS

Are there Different Effects of Acarbose and Voglibose on Serum Levels of Digoxin in a Diabetic Patient With Congestive Heart Failure?

α -Glucosidase inhibitors (α -GI), such as acarbose and voglibose, are widely used in diabetic patients to suppress postprandial hyperglycemia by interfering with carbohydrate-digesting enzymes, thus delaying glucose absorption (1). Recently, acarbose and voglibose were reported to have different effects on the absorption of digoxin; acarbose has been shown to decrease the absorption of coadministered digoxin, whereas voglibose has been demonstrated to have no such effect (2–5). We describe here a diabetic patient with congestive heart failure whose serum digoxin concentration responded differently to acarbose and voglibose.

An 82-year-old man with type 2 diabetes and congestive heart failure was treated with voglibose (0.9 mg/day) and digoxin. The serum level of digoxin remained within the therapeutic range (0.8–2.0 ng/ml). However, we decided to administer acarbose (300 mg/day) in place of voglibose because of high levels of HbA_{1c}. The decision to switch from voglibose to acarbose was prompted by data from our earlier study, which demonstrated that acarbose (300 mg/day) has a stronger effect than voglibose (0.9 mg/day) on suppressing postprandial hyperglycemia (Y.N., T.H., unpublished data). Thereafter, the HbA_{1c} level was improved by acarbose without flatulence and abdominal distention. However, subtherapeutic levels of digoxin (0.2–0.4 ng/ml) were found without changing the digoxin dosage. The patient showed no sign of worsening congestive heart failure. The patient asserted that he was taking the medications regularly according to the instructions, so compliance to the regimen did not appear to be the problem. We suspected the occurrence of a pharmacokinetic drug-drug interaction between acarbose and digoxin, a phenomenon previ-

ously described in earlier reports (2–4); therefore, we switched from acarbose back to voglibose (0.9 mg/day). Contrary to our expectations, the serum level of digoxin 1 month after voglibose readministration remained within the subtherapeutic range (0.3 ng/ml).

Miura et al. (3) reported that administering acarbose reduces the absorption of digoxin. In a report on two patients who showed subtherapeutic levels of digoxin induced by acarbose, Ben-Ami et al. (4) proposed the following mechanisms to explain the phenomenon: 1) coadministration with acarbose increases gastrointestinal motility, leading to decreased absorption of digoxin, and 2) acarbose interferes with the hydrolysis of digoxin before its absorption, thereby altering the release of the corresponding genine and affecting the reliability of the digoxin laboratory test. However, another type of α -GI voglibose was shown not to reduce the level of digoxin (5), casting doubt on the hypotheses from Ben-Ami et al. The most interesting finding in our case is that the level of digoxin was essentially unchanged after switching back from acarbose to voglibose. We have no knowledge of the mechanism behind this phenomenon; further studies are needed to clarify it. Although the precise mechanism of acarbose-induced reduction of digoxin levels remains unknown, voglibose should be recommended for diabetic patients with digoxin coadministration. If acarbose is needed, the dosage of digoxin and the timing of its administration should be considered.

YUKIHIRO NAGAI, MD, PHD
TETSUO HAYAKAWA, MD, PHD
TOSHIO ABE, MD, PHD
GAKUJI NOMURA, MD, PHD

From the Department of Internal Medicine, Kanazawa Municipal Hospital, Ishikawa, Japan.

Address correspondence to Yukihiro Nagai, MD, Department of Internal Medicine, Kanazawa Municipal Hospital, 3-7-3 Heiwa-machi, Kanazawa, Ishikawa, Japan 921-8105. E-mail: ynagai@p2223.nsk.ne.jp.

References

1. Mooradian AD, Thurman JE: Drug therapy of postprandial hyperglycemia. *Drugs* 57:19–29, 1999
2. Serrano JS, Jimenez CM, Serrano MI, Balboa B: A possible interaction of potential clinical interest between digoxin and acarbose. *Clin Pharmacol Ther* 60:589–592, 1996
3. Miura T, Ueno K, Tanaka K, Sugiura Y, Mizutani M, Takatsu F, Takano Y, Shibakawa M: Impairment of absorption of digoxin by acarbose. *J Clin Pharmacol* 38:654–657, 1998
4. Ben-Ami H, Krivoy N, Nagachandran P, Roguin A, Edoute Y: An interaction between digoxin and acarbose (Letter). *Diabetes Care* 22:860–861, 1999
5. Kusumoto M, Ueno K, Fujimura Y, Kameda T, Mashimo K, Takeda K, Tatami R, Shibakawa M: Lack of kinetic interaction between digoxin and voglibose (Letter). *Eur J Clin Pharmacol* 55:79–80, 1999

Effect of Chitosan on Plasma Lipoprotein Concentrations in Type 2 Diabetic Subjects With Hypercholesterolemia

Hypercholesterolemia is a well-known major cardiovascular risk factor in patients with type 2 diabetes (1). Step I of the National Cholesterol Educational Program (2), the restriction of fat and cholesterol intake, is usually recommended as the initial treatment to lower blood cholesterol. Therefore, dietary intervention is the first-line treatment, and, in addition to traditional hypolipidemic agents, there is the emerging role of dietary fiber in the hypolipidemic effect. Chitosan, the main component of crab and shrimp shells, is a polymer containing glucosamine units that have high positive charge densities in acidic solutions. The positive charge of chitosan interacts with negative surfaces, such as lipids. We studied the effects of chitosan on the plasma lipoprotein concentrations in subjects with type 2 diabetes who had hypercholesterolemia.

We recruited 40 subjects with type 2 diabetes and hypercholesterolemia, of which 33 completed the study. All subjects had received oral hypoglycemic agents for at least 1 year and were in stable condition. Glycemic control was kept constant, and the subjects maintained their routine eating habits throughout the course of the study. The inclusion criterion was having a fasting plasma glucose level of ≤ 10 mmol/l with hypercholesterolemia. Subjects were recruited if their LDL cholesterol level remained >3.36 mmol/l after dietary control for 4–6 weeks. In experiment A, 19 subjects underwent a mixed

Table 1—Prevalence and adjusted odds ratio for diabetes in relation to age and resident area among Canadian men and women

	Men			Women		
	n	Prevalence (95% CI)	Adjusted* OR (95% CI)	n	Prevalence (95% CI)	Adjusted* OR (95% CI)
Age (years)						
40–49	6,067	2.2 (1.6–2.9)	1.0	6,232	2.4 (1.6–3.1)	1.0
50–59	4,433	6.6 (4.8–8.5)	2.9 (1.9–4.4)	4,947	3.7 (2.8–4.6)	1.2 (0.7–2.0)
60–69	3,655	9.8 (7.9–11.8)	4.2 (2.5–6.9)	4,324	8.1 (6.4–9.7)	2.3 (1.3–3.8)
70–79	2,613	13.1 (10.2–16.0)	5.5 (2.9–10.6)	3,889	9.7 (7.6–12.0)	2.5 (1.3–4.8)
80+	962	14.4 (6.5–22.3)	6.0 (2.4–14.7)	1,899	7.2 (5.4–9.0)	1.8 (0.9–3.4)
Resident area						
Rural	13,421	6.5 (5.6–7.5)	1.0	16,674	5.08 (4.5–5.7)	1.0
Urban	4,301	7.1 (5.2–9.0)	1.1 (0.8–1.5)	4,606	5.39 (4.4–6.4)	1.0 (0.8–1.3)
Total	17,730	6.6 (5.8–7.5)	—	21,291	5.13 (4.6–5.7)	—

*Adjusted by income adequacy, education level, employment status, BMI, and physical activity. OR, odds ratio.

nique was used to take the design effect into consideration (6).

The overall prevalence (95% CI) was 6.6% (5.8–7.5%) for men and 5.1% (4.6–5.7%) for women. The prevalence increased with increasing age in both sexes, and leveled off for women aged 80 years or older (Table 1). The odds ratio (95% CI) for men compared with women was 1.60 (1.33–1.91) after adjusting for covariates. Men and women living in rural and urban areas had similar prevalences of diabetes.

In the last two decades, type 2 diabetes had been profoundly studied in specific populations, especially aboriginal people, in Canada. This analysis was based on data from a representative sample of the Canadian population and demonstrated a difference in distribution of diabetes between men and women nationally. The reasons for the increased risk of diabetes in men are not known. Obesity is one of the major risk factors for type 2 diabetes (1). The prevalence of overweight (BMI ≥25 kg/m²) is higher in men than in women in Canada (60 vs. 40%) (7), which may be a partial explanation. Men visited their dietitians less frequently (8), and less than half of men compared with almost two-thirds of women with a BMI >27 kg/m² were trying to lose weight (9). A similar prevalence in rural and urban areas may indicate there is not much difference in determinants of the disease between two areas.

The prevalence of diabetes has been steadily increasing in Canada (10). The prevalence of diabetes in aging men is increasing more rapidly than that in aging women. This suggests that senior men

should be given more attention in terms of disease control and prevention.

MEI TANG, MD, MSc
YUE CHEN, MD, PHD

From the Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ontario, Canada.

Address correspondence to Mei Tang, MD, Msc, Department of Epidemiology and Community Health, Faculty of Medicine, University of Ottawa, 451 Smyth Rd., Ottawa, Ontario K1H 8M5, Canada. E-mail: meitang@zeus.med.uottowa.ca.

Acknowledgments— This research was supported by a National Health Research and Development Program Grant (6606–06–1998/2640023).

We thank Ms. Colette Koeune of Statistics Canada for her assistance in remote access to the NPHS data.

References

1. Myers AR: *Medicine*. 3rd ed. Baltimore, MD, Williams & Wilkins, 1997, p. 475–492
2. Harris MI: Non-insulin-dependent diabetes mellitus in black and white Americans. *Diabetes Metab Rev* 6:71–90, 1990
3. Harris MI, Goldstein DE, Flegal KM, Little RR, Cowie CC, Wiedmeyer H, Eberhardt Ms, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey. *Diabetes Care* 21:518–524, 1998
4. Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W: Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. *J Epidemiol Community Health* 54:173–177, 2000

5. Statistics Canada: National Population Health Survey 1996–97. Ottawa, Ontario, Canada, Health Statistics Division, 1997
6. Rao JNK, Wu CFJ, Yue K: Some recent work on resampling methods for complex surveys. *Survey Methodology* 18:209–227, 1992
7. Chen Y, Dales R, Krewski D: Increased effects of smoking and obesity on asthma among female Canadians: the National Population Health Survey (NPHS) 1994–1995. *Am J Epidemiol* 150:255–262, 1999
8. Lo R, MacLean D: A survey of people with diabetes in northern New South Wales: problems with self-care. *Int J Nurs Pract* 2: 11–20, 1996
9. Green KL, Cameron R, Polivy J, Cooper K, Liu L, Leiter L, Heatherton T: Weight dissatisfaction and weight loss attempts among Canadian adults. *CMAJ* 157 (Suppl. 1):S17–S25, 1997
10. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. *Diabetes Care* 21:1414–1424, 1998

Prevalence of GAD Autoantibodies in Women With Gestational Diabetes

A retrospective analysis

Autoantibodies to GAD (GADa) have been the source of considerable attention because of their association with the development of type 1 diabetes. As a consequence, several groups have been interested in the relationship between GADa in women with gestational diabetes and the subsequent occurrence of permanent diabetes. Interestingly, publications on this subject, emanating primarily from Europe, have been notable for their lack of unanimity concerning the rates of autoantibody positivity. These rates have ranged from 0% GADa positivity in gestational diabetic women from northern Italy (1) to a high of 10% in gestational diabetic women from a German multicenter study (2). A study in Denmark reported an incidence of 2.2% GADa positivity in sera from gestational diabetic women (3). In all likelihood, such discrepancies can be attributed in whole or in part to distinct population characteristics and differences in laboratory methodology.

In view of the experience of the European investigators vis-à-vis the aforementioned rates of GADa positivity, we thought it would be of interest to deter-

than 1 week per school year than their nondiabetic siblings. The close correlation in absenteeism between diabetic children and their nondiabetic siblings suggests that family attitudes may be a major factor in determining school attendance. Factors contributing to differences in school attendance may include parental overprotection, parental philosophy regarding academics, and the quality of communication between parents and teachers. To gain greater insight into this issue, a more extensive study that attempts to quantify family attitudes and family unit function is needed.

JANE VETISKA, BSC
LAURA GLAAB, BNSC
KUSIEL PERLMAN, MD, FRCPC
DENIS DANEMAN, MB, BCH, FRCPC

From the Division of Endocrinology, the Hospital for Sick Children, Toronto, Ontario, Canada.

Address correspondence to Dr. Denis Daneman, Division of Endocrinology, Hospital for Sick Children, University of Toronto, 555 University Ave., Toronto, Ontario M5G 1X8, Canada. E-mail: denis.daneman@sickkids.on.ca.

References

1. Weitzman M: School absence rates as outcome measures in studies of children with chronic illness. *J Chronic Dis* 39:799–808, 1986
2. Weitzman M, Walker DK, Gortmaker S: Chronic illness, psychosocial problems, and school absences: results of a survey of one county. *Clin Pediatr* 25:137–141, 1986
3. Cook BA, Schaller K, Krischer JP: School absence among children with chronic illness. *J Sch Health* 55:265–267, 1985
4. Ryan C, Longstreet C, Morrow L: The effects of diabetes mellitus on the school attendance and school achievement of adolescents. *Child Care Health Dev* 11:229–240, 1985
5. Brown R: More on secondary school absenteeism. *Research Review: The Weekly Circular*. 24 November 1995, p. 1–2

“Lady-like”

Is there a latent autoimmune diabetes in the young?

Latent autoimmune diabetes in adults is often characterized by a mild manifestation and a long period of preserved β -cell function (1). In contrast, autoimmune diabetes in childhood is normally seen as a rapid progressive disease

with immediate insulin deficiency at diagnosis. Longer periods of remission after initial insulin therapy for up to several years have been described. In a series of 747 children with newly diagnosed type 1 diabetes (2), only 3.4% of the autoantibody-positive children had clinical remissions 18 months after diagnosis (defined as a daily insulin dose $<0.5 \text{ U} \cdot \text{kg}^{-1} \cdot \text{day}$). This statistic suggests that insulin independence >1 year after initial diagnosis of diabetes is a rather rare event in children with type 1 diabetes.

We have studied two newly diagnosed type 1 diabetic children with multiple and high-titer autoantibodies and typical high-risk HLA haplotypes for autoimmune diabetes. Nevertheless, the children have been insulin independent for up to one year. In both children, stable residual β -cell function without insulin therapy was preserved. The study of these patients questions the concept of rapidly progressive type 1 diabetes in autoimmune diabetes during childhood and adds a point of caution for the interpretation of ongoing trials for diabetes prevention in so-called high-risk prediabetic patients (3).

Patient 1, a girl aged 8 years 7 months, was diagnosed with diabetes in April 1999 with a fasting blood glucose of 7 mmol/l and an HbA_{1c} level of 8.0% (upper limit in our laboratory 6.2%). She had no polyuria or polydipsia and no weight loss at this time. Furthermore, no ketonuria or ketoacidosis was present. Basal C-peptide was measured at 0.76 nmol/l and could be stimulated by 1 mg glucagon intravenously to reach 1.47 nmol/l. Family history revealed type 2 diabetes in both grandparents on the maternal side, who had been diagnosed at 46 and 60 years, respectively, and treated by oral hypoglycemic drugs. The girl herself was overweight at diagnosis (BMI 28 kg/m²). Therefore, type 2 diabetes or maturity-onset diabetes of the young was suspected at this time, and a calorie-reduced diet and physical exercise were prescribed. Surprisingly, high-titer autoantibodies were detected in the patient's serum (ICA >40 Juvenile Diabetes Foundation units [JDF-U], GADA 101 U, and IA2A 28 U) (methods and workshop data of assays in [4]). In addition, the HLA type of the patient was DRB1*0301/0401-DQB1*0201/0302. This represents the highest association for autoimmune type 1 diabetes. We found no other autoantibodies typical for polyendocrine autoimmunity. In July 1999, the

girl had lost 6 kg of weight, her HbA_{1c} had normalized to 5.9%, and all blood glucose levels (fasting and postprandial) were in the normal range. In August 1999, we measured a postprandial C-peptide level of 2.86 nmol/l. This level suggests complete recovery of β -cell function. In April 2000, 12 months after initial diagnosis, the girl was still insulin-free with normal values for fasting blood glucose and HbA_{1c}, but the 2-h blood glucose level of the oral glucose tolerance test (OGTT) was 11.9 mmol/l, again in the diabetic range. The islet cell-specific autoantibodies were consistently positive (islet cell antibody, GAD, and IA2) throughout this period.

Patient 2 was a girl aged 8 years 5 months who was diagnosed in January 1999 with a blood glucose level of 17.6 mmol/l from an OGTT and an HbA_{1c} of 6.4%. In the family history, the grandmother on the paternal side had type 2 diabetes. The girl was also overweight with a BMI of 22.1 kg/m². She was treated with diet and released from the hospital after weight reduction without further therapy. Five months later, she was admitted to a diabetes rehabilitation clinic. There, she was still insulin-free and was considered not to have diabetes after all. But after 3 months, in September 1999, she was again admitted to the hospital with a fasting blood glucose level of 11.8 mmol/l. Her blood glucose level increased to 22.8 mmol/l during an OGTT. The HbA_{1c} level was then 8.6%. She had type 1 diabetes-associated HLA haplotype DR3/4, DQ*0201/0302, and high-titer autoantibodies in her serum (ICA >40 JDF-U, GAD 7 U, and IA2 37 U). Therefore, the diagnosis of type 1 diabetes was made according to the criteria of the American Diabetes Association and the World Health Organization (5). The C-peptide level from the OGTT was basal 0.61 nmol/l and increased to 0.76 nmol/l after glucose load. Therefore, insulin deficiency has been recognized and insulin therapy started 9 months after the first diagnosis with $0.15 \text{ U} \cdot \text{kg}^{-1} \cdot \text{day}$. Three months later, her HbA_{1c} was 6.5%, and insulin doses were reduced to $0.05 \text{ U} \cdot \text{kg}^{-1} \cdot \text{day}$.

Both cases demonstrate that the autoimmune destruction of islets can also be slowly progressive in childhood diabetes. Even insulin independency may be observed for up to 1 year. Others have reported nonprogression of subclinical β -cell dysfunction in relatives of type 1 diabetic patients and called this phenom-

“silent diabetes” (6). We found that even overt diabetes in children may be seemingly reversible for some months. Furthermore, being severely overweight may add some kind of insulin resistance to the pathogenesis and suggests a combination of type 1 and type 2 diabetes. This problem will be seen more often in the future because of the increasing frequency of overweight children in many countries and may complicate diagnoses. These patients show how heterogeneous the natural history of autoimmune diabetes may be in so-called high-risk prediabetic patients (multiple autoantibodies of high-titer and HLA alleles associated with high risk for type 1 diabetes) currently studied in diabetes prevention trials (3). We suggest allowing for such slow progression when case ratios are calculated in prevention trials.

TOBIAS LOHMANN, MD
 UTE NIETZSCHMANN, MD
 WIELAND KIESS, MD

From the Department of Internal Medicine III (T.L.) and the Childrens Hospital (U.N., W.K.), University of Leipzig, Leipzig, Germany.

Address correspondence to Tobias Lohmann, MD, Department of Internal Medicine III, University of Leipzig, Ph.-Rosenthal-Str. 27, 04103 Leipzig, Germany.

References

1. Tuomi T, Carlsson A, Li H, Miettinen A, Nilsson A, Nissen M, Ehrnström B-O, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen M-J, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. *Diabetes* 48:150–157, 1999
2. Sabbah E, Savola K, Kulmala P, Veijola R, Vähäsola P, Karjalainen J, Akerblom HK, Knip M, and the Childhood Diabetes in Finland Study Group: Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed Type 1 diabetes. *J Clin Endocrinol Metab* 84:1534–1539, 1999
3. DPT-1 Study Group: The Diabetes Prevention Trial-Type 1 diabetes (DPT-1): implementation of screening and staging of relatives. *Transplant Proc* 27:33–77, 1995
4. Lohmann T, Seissler J, Verlohren HJ, Schröder S, Rötger J, Dähn K, Morgenthaler N, Scherbaum WA: Distinct genetic and immunological features in patients with insulin-dependent diabetes below and above age 40 at onset. *Diabetes Care* 20:524–529, 1997
5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:

Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 20:1183–1197, 1997

6. McCulloch DK, Klaff LJ, Kahn SE, Schoenfeld SL, Greenbau CJ, Mauseth RS, Benson EA, Nepom GT, Shewey L, Palmer JP: Nonprogression of subclinical β -cell dysfunction in first-degree relatives of IDDM patients. *Diabetes* 39:549–556, 1990

Relevance of the Treatment Facility for Disease-Related Knowledge of Diabetic Patients

The treatment of diabetes is predominantly a form of self-treatment carried out by patients. For this reason, being sufficiently informed is considered to be a prerequisite for a patient's successful management of his or her blood glucose levels (1–3). It is a known fact that structured training courses can improve treatment-related knowledge, at least in the short term (4), whereas the physician's qualification and the quality of the physician–patient relationship is more likely to be of fundamental importance for the procurement of knowledge on the part of the patient (5–7). However, the ultimate decisive factor is the amount of information patients have managed to acquire under routine conditions. We examined whether the degree of specialization at the facility where diabetic patients receive treatment has any relevance for patients' level of knowledge (8).

The present study examines a sampling of 625 diabetic patients. A total of 174 patients were recruited from the diabetes outpatient center at the Charité University Polyclinic, 264 patients were recruited from three specialist practices, and 187 patients were recruited from 28 general practitioner practices. The three specialist practices and 194 general practitioners were contacted randomly using the Medical Handbook for Berlin (9) until 3 specialists and 30 general practitioners were recruited in the Berlin metro area. Two general practitioners later refused to take part in the study. The record was compiled consecutively over a period of 3 months; the near-complete registration of patients treated at the polyclinic required a period of 9 months. Sociodemographic variables (e.g., age, sex, and school educa-

tion) were equally distributed, except for a slight predominance among men in specialized facilities. All patients were asked to fill out a standardized questionnaire to test their knowledge (10) while waiting to meet with their physician. The 90-item questionnaire is based on comparable Anglo-American questionnaires (11,12) and assesses knowledge in the following areas: causes/pathophysiology, insulin/effects of insulin, insulin injection/storage, nutrition, physical activity, personal control over metabolic functions, hyperglycemia, hypoglycemia, illnesses, insulin adaptation, and consequential damages. Patients who did not have insulin therapy were given an adapted version that excluded questions on insulin treatment.

In terms of treatment-related knowledge dependent on the facility where they received treatment, the mean values, corrected for age, sex, and education, showed hardly any disparity between type 1 diabetic patients and non-insulin-requiring type 2 diabetic patients, even when the impact of structured training was eliminated in the calculation (Table 1). Conversely, insulin-dependent type 2 diabetic patients treated in specialized facilities had a significantly higher level of knowledge (~16% more correct answers) than those treated by a general practitioner. This difference can be partially explained by the fact that specialized facilities apply more intensified forms of therapy (intensified conventional insulin treatment and/or continuous subcutaneous insulin infusion) and frequent structured training programs; these two characteristics, independent of each other, were associated with a higher level of knowledge. If these effects are excluded, differences still exist between treatment facilities, but they are not significant.

To summarize, in terms of acquiring extensive knowledge of diabetes, type 1 and non-insulin-dependent type 2 diabetic patients do not benefit from a degree of specialization in the therapeutic facility. However, insulin-requiring type 2 diabetic patients treated in specialized clinics have a much higher level of knowledge due to the enhanced utilization of intensified forms of therapy and structured training.

MATTHIAS ROSE, MD
 MARTIN HILDEBRANDT, MD
 HERBERT FLIEGE, PHD
 BARBEL SEIDLITZ, MD
 LIVIA COTTA, MD

The allele frequency of the Met⁴¹⁶ → Val variant was 0.108 in diabetic subjects (Met/Met was 1,221, Met/Val was 285, and Val/Val was 23 of 1,529 subjects) and 0.102 in control subjects (Met/Met was 723, Met/Val was 172, and Val/Val was 6 of 901 subjects). There was no statistical difference in allele frequency of the Met⁴¹⁶Val variant between the diabetic and control groups (the odds ratio for the association of the Val allele with type 2 diabetes was 1.1067 [95% CI 0.882–1.291], $P = 0.50233$ vs. normal control group [χ^2 test]). In diabetic subjects, there were no differences in age, sex, age at onset of diabetes, and the HbA_{1c}, fasting plasma glucose, and serum lipid levels between the groups with or without the Met⁴¹⁶ → Val substitution. Among the clinical parameters related to insulin resistance, BMI, maximum BMI, waist-to-hip ratio, and insulin resistance measured by the homeostasis model assessment (HOMA-IR) (7) also showed no significant differences.

These results suggest that the Met⁴¹⁶ → Val variant is not likely to be a single-nucleotide polymorphism associated with susceptibility to type 2 diabetes. Moreover, this polymorphism does not affect the insulin sensitivity assessed by HOMA-IR in the present study, although the previous study showed the association between this variant and decreased insulin sensitivity evaluated by the minimal model analysis (5).

STUDY GROUP FOR THE IDENTIFICATION OF TYPE 2 DIABETES GENES IN JAPANESE

The Study Group for the Identification of Type 2 Diabetes Genes in Japanese consists of the following constituents: Hiroyuki Mori, Hiroshi Ikegami, Susumu Seino, Jun Takeda, Yutaka Seino, Toshiaki Hanafusa, Takuya Awata, Takashi Kadowaki, Nobuhiro Yamada, Naoko Iwasaki, Tokio Sanke, Kishio Nanjo, Yoshitomo Oka, Eiichi Maeda, and Masato Kasuga.

Address correspondence to Masato Kasuga, Second Department of Internal Medicine, Kobe University School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. E-mail: kasuga@med.kobe-u.ac.jp.

Acknowledgments — The Study Group for the Identification of Type 2 Diabetes Genes in Japanese is supported by Health Sciences Research Grants (Research on Human Genome and Gene Therapy) from the Ministry of Health and Welfare in Japan.

References

1. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG: Quantitation of muscle glycogen synthesis in normal

subjects and subjects with non-insulin-dependent diabetes by ¹³C nuclear magnetic resonance spectroscopy. *N Engl J Med* 322:223–228, 1990

2. Groop LC, Kankuri M, Schalin-Jantti C, Ekstrand A, Nikula-Ijas P, Widen E, Kuismann E, Eriksson J, Franssila-Kallunki A, Saloranta C, Koskimies S: Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. *N Engl J Med* 328:10–14, 1993
3. Orho M, Nikula-Ijas P, Schalin-Jantti C, Permtt MA, Groop LC: Isolation and characterization of the human muscle glycogen synthase gene. *Diabetes* 44:1099–1105, 1995
4. Bjorbaek C, Echwald SM, Hubricht P, Vestergaard H, Hansen T, Zierath J, Pedersen O: Genetic variants in promoters and coding regions of the muscle glycogen synthase and the insulin-responsive GLUT4 genes in NIDDM. *Diabetes* 43:976–983, 1994
5. Shimomura H, Sanke T, Ueda K, Hanabusa T, Sakagashira S, Nanjo K: A missense mutation of the muscle glycogen synthase gene (M^{416V}) is associated with insulin resistance in the Japanese population. *Diabetologia* 40:947–952, 1997
6. Rissanen J, Pihlajamaki J, Heikkinen S, Kekalainen P, Mykkanen L, Kuusisto J, Kolle A, Laakso M: New variants in the glycogen synthase gene (Gln71His, Met⁴¹⁶Val) in patients with NIDDM from eastern Finland. *Diabetologia* 40:1313–1319, 1997
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentration in man. *Diabetologia* 28:412–419, 1985

Venlafaxine in Treatment of Severe Painful Peripheral Diabetic Neuropathy

Venlafaxine is an antidepressant that was recently demonstrated to be an effective remedy for painful diabetic neuropathy (1). This report is on a 26-year-old woman who has had type 1 diabetes since the age of 13 years. She was a non-smoker and had no long-term diabetic complications. In association with bulimia and high blood glucose levels, she developed burning pains and pronounced tenderness in her legs and arms, particularly in the distal part of her left leg. There was also distal edema in both legs, mostly on the left side.

The patient received the following ambulatory treatment at our department of medicine: paracetamol and dextropropox-

ifen for 7 months; amitriptylin, klonazepan, gabapentin, and diclofenak for 4 months; and tramadol and buprenorfin for 3 months. She then had eight different analgesics at the upper level of the recommended doses, but they had no effect on her pains. She could only find relief when she put her legs in buckets of cold water for most of the night and day; otherwise, she was bedridden. When she took her legs out of the buckets, the pain returned. After 7 months, she developed pronounced orthostatism and was entirely dependent on her family. During the period of severe pain, she developed preproliferative retinopathy and moderate signs of distal sensory, autonomic, and motor neuropathy.

Her pains increased despite taking the eight analgesics, and her health deteriorated. The only pharmaceutical left to try was mexiletinhydrochloride (2), but her pronounced orthostatism was a contraindication. However, I had recently read the report on venlafaxine (1); when her health further deteriorated, there was no alternative, and a rapid decision was necessary. During her first week on venlafaxine depot at 75 mg/day (later increased to 3 × 75 mg/day), an improvement was noticed, including an improvement in her visual analogue scale tests. Now, 7 months later, her health is continuously better. She still has distal pains, but she regards them as controllable. There have been some setbacks, such as when she walked too much and severe pain in the feet returned for some days, or when she had bulimia for a short time. The number of her analgesics could have been continuously reduced. However, we noted that apart from venlafaxine, the only pharmaceutical that was not possible to reduce was gabapentin; the patient experienced a return of pain both times it was reduced.

In conclusion, we found that, when no other analgesics helped in a diabetic patient with severe distal painful neuropathy, venlafaxine had a good results from the start of the treatment and possibly in combination with gabapentin. In future studies, these factors associated with venlafaxine should be validated.

FOLKE LITHNER, MD, PHD

From the Department of Medicine, Umeå University Hospital, Umeå, Sweden.

Address correspondence to Folke Lithner, MD, PhD, Umeå University Hospital, Umeå S-901 85, Sweden. E-mail: folke.lithner@medicin.umu.se.

References

1. Davis JL, Smith RL: Painful peripheral diabetic neuropathy treated with venlafaxine HCL extended release capsules. *Diabetes Care* 22:1909–1910, 1999
2. Oskarsson P, Ljunggren J, Lins P, the Mexiletine Study Group: Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. *Diabetes Care* 20:1594–1597, 1997

Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose by Error Grid Analysis

Comment on constructing the “upper A-line”

Error grid analysis for the evaluation of systems for the self-monitoring of blood glucose (SMBG) was developed in the late 1980s (1,2) and, since then, has been applied by many scientists (3). To construct an error grid plot for our own purposes (Fig. 1), we screened the respective studies and were surprised to find that the upper A-line was often incorrectly constructed (4,5). Whereas the correct upper A-line corresponds to a clinically acceptable +20% deviation of a SMBG from the reference, those authors showed a line that corresponds to a +25% deviation, resulting in an overoptimistic interpretation of SMBG.

The reason for this error might be the following. Most authors use an error grid plot with an equally scaled x- and y-axis and start its construction by drawing the lower A-line (–20% deviation) using the formula $y = 0.8 \cdot x$. Thus, in Fig. 1, the lower A-line extends from the (x,y) pair (3.9,3.12) to (25,20). Then, one may be tempted (because of the y-scale limitation) to construct the upper A-line by simply reversing the x/y coordinates (4,5), which would result in the points (3.12,3.9) and (20,25) (represented by the bold broken line in Fig. 1). However, this line represents a +25% deviation from the reference. Correctly, one needs to calculate the respective points with the formula $x = y/1.2$. Thus, in our case, the correct upper A-line extends from (3.25, 3.9) to (20.83, 25) (represented by the full bold line in Fig. 1). A correct construction has been demonstrated previously by Brunner et al. (6).

In view of this observation, we investigated whether the original article by




Figure 1—Error grid analysis according to Clarke et al. (1). The original upper A-line is indicated by --- and the correct upper A-line by —. Detailed interpretations of the different zones (A–E) have been published previously (1–3).

Clarke et al. (1) would contain the same error (i.e., an upper A-line that represents a +25% deviation). To this purpose, we graphically superimposed a self-constructed analog of the Clarke et al. figure with the original one and read the highest point of the upper A-line from the original (~[330,410] in original units [milligrams per deciliter]; the correct point should be [330,396]). Both indicated that the original figure might be erroneous. However, the quality of the graph in the original articles (1,2) made the reading of the point difficult. Definitive proof of the erroneous upper A-line (coordinates of the upper point [330,412], which equal $y = 1.25 \cdot x$) was found in a more detailed figure published later by the same group (7).

From the above, readers should be aware that error grid plots published in the past may contain an erroneous upper A-line, and conclusions taken from such graphs should be interpreted with caution.

DIETMAR STÖCKL, PHD
KATY DEWITTE, PHARM
COLETTE FIERENS, PHARM
LINDA M. THIENPONT, PHD

From the Laboratorium voor Analytische Chemie, Faculteit Farmaceutische Wetenschappen, Universiteit Gent, Harelbekestraat 72, 9000 Gent, Belgium.

Address correspondence to Linda M. Thienpont, PhD, Laboratorium voor Analytische Chemie, Faculteit Farmaceutische Wetenschappen, Universiteit Gent, Harelbekestraat 72, Gent 9000, Belgium. E-mail: linda.thienpont@rug.ac.be.

References

1. Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL: Evaluating clinical accuracy of systems for self-monitoring of blood glucose. *Diabetes Care* 10:622–628, 1987
2. Cox DJ, Richards FE, Gonder-Frederick LA, Julian DM, Carter WR, Clarke WL: Clarification of error-grid analysis. *Diabetes Care* 12:235–236, 1989
3. Cox DJ, Gonder-Frederick LA, Kovatchev BP, Julian DM, Clarke WL: Understanding error grid analysis. *Diabetes Care* 20:911–912, 1997
4. Trajanoski Z, Brunner GA, Schaupp L, Ellmerer M, Wach P, Pieber TR, Kotanko P, Skrabal F: Open-flow microperfusion of subcutaneous adipose tissue for online continuous ex vivo measurement of glucose concentration. *Diabetes Care* 20:1114–1121, 1997
5. Weitgasser R, Gappmayer B, Pichler M: Newer portable glucose meters: analytical

higher mean BMI. Numerous data support the relationship between both tumor necrosis factor- α (TNF- α) (2–4) and TNFR2 (5,6) and obesity-related insulin resistance. Therefore, one would expect to find elevated TNF- α and TNFR2 levels in type 2 diabetic patients, especially if such patients are of an older age-group. Thus, a multivariate analysis that would take into account BMI, age, insulin resistance status, and the presence of the TNFR2 A2 allele should be conducted. The results of such an analysis would be of special interest to us, because we could not detect an association between age and TNF- α levels in nondiabetic obese children (2).

Wael Taha, MD
 IDO Paz-Priel, MD
 Henry Anhalt, DO

From the Division of Pediatric Endocrinology, Department of Pediatrics, Maimonides Medical Center, Brooklyn, New York.

Address correspondence to Henry Anhalt, DO, 977 48th St., Brooklyn, NY 11219.

References

1. Fernandez-Real JM, Vendrell J, Ricart W, Broch M, Gutierrez C, Casamitjana R, Oriola J, Richart C: Polymorphism of the tumor necrosis factor- α receptor 2 gene is associated with obesity, leptin levels, and insulin resistance in young subjects and diet-treated type 2 diabetic patients. *Diabetes Care* 23:831–837, 2000
2. Paz-Priel I, Khan N, Taha W, Lashiker L, Chin D, Anhalt H: The relationship between serum tumor necrosis factor alpha levels and anthropometric measurement in morbidly obese children. *Pediatr Res* 47:135A, 2000
3. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor alpha: direct role in obesity-linked insulin resistance. *Science* 259:87–91, 1993
4. Uysal KT, Weisbrock, Marino MW, Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF alpha function. *Nature* 389:610–614, 1997
5. Fernandez-Real JM, Molina A, Broch M, Ricart W, Gutierrez C, Casamitjana R, Vendrell J, Soler J, Gómez-Sáez JM: Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. *Diabetes* 48:1108–1112, 1999
6. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM: Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. *Diabetes* 46:451–455, 1997

Plasma Tumor Necrosis Factor- α Receptor 2 Levels Are Associated With Age

Response to Taha, Paz-Priel, and Anhalt

Taha, Paz-Priel, and Anhalt wonder whether the relationship between plasma levels of the soluble fraction of tumor necrosis factor- α receptor 2 (sTNFR2) and age was merely due to an unequal distribution of the subjects among groups. In our previous article (1), we reported that 50% of the subjects were control subjects and 50% were type 2 diabetic subjects. The relationship between sTNFR2 and age was similar in both groups and remained so after excluding the diabetic patients. To clarify such a relationship, we have further evaluated 261 control subjects with BMIs <40 kg/m²,

normal glucose levels, no medication, and no acute illness in the previous month. In these subjects, sTNFR2 significantly correlated with age ($r = 0.27, P < 0.0001$) (Fig. 1), and this relationship was even stronger in women (107 subjects, $r = 0.34, P < 0.0001$). A similar correlation coefficient between sTNFR2 levels and age has been described in a recent article (2).

The results reported in the abstract by Taha, Paz-Priel, and Anhalt (3) are in sharp contrast with the findings of Paolisso et al. (4), who found a correlation between plasma TNF- α and age ($r = 0.64, P < 0.001$) that was independent of sex and body fat. These differences may be attributed to the pediatric age of the patients evaluated and to the inclusion of morbidly obese children in Taha, Paz-Priel, and Anhalt's study. In fact, adipose tissue expression of TNF- α is paradoxically decreased in adult subjects with morbid obesity (5).

José-Manuel Fernández-Real, MD, PhD
 Joan Vendrell, MD, PhD
 Wifredo Ricart, MD




Figure 1—Correlation between plasma sTNFR2 levels and age. $r = 0.27; P < 0.0001$.

We could not find any other differences after stratification of ICA or combined ICA/GADA status. Further analysis revealed that the subgroup of patients with HbA_{1c} value above the mean for the whole group (i.e., 10.7%) and with longer duration of symptoms (>2 weeks) showed higher insulin requirements and lower C-peptide levels at follow-up with no influence of antibody status. The latter data are clearly discordant with recent findings in a Japanese study (3). Thus, no major differences are found between antibody-positive and antibody-negative subjects at onset in our cohort.

Our results are clearly concordant with recent studies in which the proportion of antibody-negative subjects at onset of type 1 diabetes in Caucasian populations is very low (3.5–7%) (1,2). This is at variance with recent data in Japanese type 1 diabetic patients for whom a novel subtype of fulminant nonautoimmune diabetes is claimed to exist (3). This novel subtype of diabetes does not seem to exist in the Caucasian population. Further, patients with type 1b diabetes, as described in the American Diabetes Association classification (5), are hardly identified in European populations of Caucasian origin. There seems to be no major differences in type 1 diabetic subjects at onset when autoimmune markers are taken

into account (1–3,6). Moreover, as recently demonstrated, markers of autoimmunity may not be present at onset but may appear later at follow-up or even may have been present in the prediabetic period (2). On these grounds, the absence of humoral autoimmune markers at onset of type 1 diabetes in Caucasian populations does not necessarily preclude the existence of an ongoing autoimmune process directed against β -cells. This group of patients may not be classified as type 1b diabetic subjects, as suggested by other investigators (2).

GEMMA CARRERAS, PHD
 DIDAC MAURICIO, MD
 ANTONIO PÉREZ, MD
 ALBERTO DE LEIVA, MD



From the Department of Endocrinology (D.M., A.P., A.d.L.) and the Department of Pediatrics (G.C.), Hospital Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.

Address correspondence to Gemma Carreras González, PhD, Department of Pediatrics, Hospital Sant Pau, Autonomous University of Barcelona, Sant Antoni M^a Claret 167, 08025 Barcelona, Spain. E-mail: gcarreras@hsp.santpau.es.

References

1. Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F, Anckaert E, Weets E, Pipeleers DG, Gorus FK, the Bel-

gian Diabetes Registry: High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. *Diabetes Care* 23:838–844, 2000

2. Tiberti C, Buzzetti R, Anastasi E, Dotta F, Vasta M, Petrone A, Cervoni M, Torresi P, Vecci E, Multari G, Di Mario U: Autoantibody negative new onset type 1 diabetic patients lacking high risk HLA alleles in a Caucasian population: are these type 1b diabetes cases? *Diabetes Metab Res Rev* 16: 8–14, 2000

3. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y: A novel subtype of type 1 diabetes mellitus characterized by rapid onset and absence of diabetes-related antibodies. *N Engl J Med* 342:301–307, 2000

4. Mauricio D, Carreras G, Pérez A, Morales J, Puig-Domingo M, de Leiva A: Association of islet-cell and glutamic-acid decarboxylase antibodies to β -cell function after the onset of type 1 diabetes in adult subjects. *Diabetes Nutr Metab* 10:189–192, 1997

5. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 20:1183–1197, 1997

6. Pozzilli P, Visalli N, Buzzetti R, Cavallo G, Marietti G, Hawa M, Leslie RDG, the IMDIAB Study Group: Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population-based study. *Metabolism* 47:1205–1210, 1998